PTC Therapeutics, Inc.: Agreed to Acquire From Sangamo Assets Primarily Related to ST-920, an AAV Gene Therapy Product Candidate for Fabry Disease >PTCT

Dow Jones2026/08/28 21:42

By:Dow Jones

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Figma CEO to speak at investor conference

Reuters•2026/08/28 22:31

Dolby Labs CEO Marc Whitten files initial beneficial ownership statement

Reuters•2026/08/28 22:02

Justice Department: Files Statement of Interest in Support of Primary Aluminum Smelter Project in Inola, Okla.

Dow Jones•2026/08/28 21:51

Which Is the Next Meme Coin to Explode? IceBull Opens an Early Presale Entry With 1250X Potential

TimesTabloid•2026/08/28 21:48